Are GLP1R agonists a panacea for obesity?

Are GLP1R agonists a panacea for obesity?

Public Health Nutrition

CME/CPD Points: 1

Please be aware that you will have to create an account and upgrade to full membership to take courses. Create an account

This is an NHS course. Users require Full Membership and NHS Membership to enrol. NHS membership is obtained via unique coupon codes provided by the NHS.

Join Dr Giles Yeo for this exciting webinar on the topic  “Are GLP1R agonists a panacea for obesity”. GLP1R agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro) are hugely effective in the treatment of obesity. Originally developed for Type 2 diabetes, these drugs also cause dramatic weight loss. 

This content is only available to members.

Lesson

Are GLP1R agonists a panacea for obesity? : Lesson 1

Length: 60 minutesAuthor: cmeComplexity: Easy

GLP1R agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro) are hugely effective in the treatment of obesity. Originally developed for Type 2 diabetes, these drugs also cause dramatic weight loss.